Maryam Aghighi1, Laura Pisani1, Ashok J Theruvath1, Anne M Muehe1, Jessica Donig1, Ramsha Khan1, Samantha J Holdsworth1, Neeraja Kambham2, Waldo Concepcion3, Paul C Grimm4, Heike E Daldrup-Link5,6. 1. Department of Radiology, Pediatric Molecular Imaging in the Molecular Imaging Program at Stanford (@PedsMIPS), Lucile Packard Children's Hospital, Stanford University School of Medicine, 725 Welch Road, Stanford, 94305, CA, USA. 2. Department of Pathology, Stanford University, Stanford, CA, USA. 3. Department of Surgery, Stanford University, Stanford, CA, USA. 4. Department of Pediatrics, Stanford University, Stanford, CA, USA. 5. Department of Radiology, Pediatric Molecular Imaging in the Molecular Imaging Program at Stanford (@PedsMIPS), Lucile Packard Children's Hospital, Stanford University School of Medicine, 725 Welch Road, Stanford, 94305, CA, USA. H.E.Daldrup-Link@stanford.edu. 6. Department of Pediatrics, Lucile Packard Children's Hospital, Stanford School of Medicine, 725 Welch Rd, Stanford, CA, 94305, USA. H.E.Daldrup-Link@stanford.edu.
Abstract
PURPOSE: To evaluate whether ultrasmall superparamagnetic iron oxide nanoparticle (USPIO)-enhanced magnetic resonance imaging (MRI) can detect allograft rejection in pediatric kidney transplant patients. PROCEDURES: The USPIO ferumoxytol has a long blood half-life and is phagocytosed by macrophages. In an IRB-approved single-center prospective clinical trial, 26 pediatric patients and adolescents (age 10-26 years) with acute allograft rejection (n = 5), non-rejecting allografts (n = 13), and normal native kidneys (n = 8) underwent multi-echo T2* fast spoiled gradient-echo (FSPGR) MRI after intravenous injection (p.i.) of 5 mg Fe/kg ferumoxytol. T2* relaxation times at 4 h p.i. (perfusion phase) and more than 20 h p.i. (macrophage phase) were compared with biopsy results. The presence of rejection was assessed using the Banff criteria, and the prevalence of macrophages on CD163 immunostains was determined based on a semi-quantitative scoring system. MRI and histology data were compared among patient groups using t tests, analysis of variance, and regression analyses with a significance threshold of p < 0.05. RESULTS: At 4 h p.i., mean T2* values were 6.6 ± 1.5 ms for native kidneys and 3.9 ms for one allograft undergoing acute immune rejection. Surprisingly, at 20-24 h p.i., one rejecting allograft showed significantly prolonged T2* relaxation times (37.0 ms) compared to native kidneys (6.3 ± 1.7 ms) and non-rejecting allografts (7.6 ± 0.1 ms). Likewise, three additional rejecting allografts showed significantly prolonged T2* relaxation times compared to non-rejecting allografts at later post-contrast time points, 25-97 h p.i. (p = 0.008). Histological analysis revealed edema and compressed microvessels in biopsies of rejecting allografts. Allografts with and without rejection showed insignificant differences in macrophage content on histopathology (p = 0.44). CONCLUSION: After ferumoxytol administration, renal allografts undergoing acute rejection show prolonged T2* values compared to non-rejecting allografts. Since histology revealed no significant differences in macrophage content, the increasing T2* value is likely due to the combined effect of reduced perfusion and increased edema in rejecting allografts.
PURPOSE: To evaluate whether ultrasmall superparamagnetic iron oxide nanoparticle (USPIO)-enhanced magnetic resonance imaging (MRI) can detect allograft rejection in pediatric kidney transplant patients. PROCEDURES: The USPIO ferumoxytol has a long blood half-life and is phagocytosed by macrophages. In an IRB-approved single-center prospective clinical trial, 26 pediatric patients and adolescents (age 10-26 years) with acute allograft rejection (n = 5), non-rejecting allografts (n = 13), and normal native kidneys (n = 8) underwent multi-echo T2* fast spoiled gradient-echo (FSPGR) MRI after intravenous injection (p.i.) of 5 mg Fe/kg ferumoxytol. T2* relaxation times at 4 h p.i. (perfusion phase) and more than 20 h p.i. (macrophage phase) were compared with biopsy results. The presence of rejection was assessed using the Banff criteria, and the prevalence of macrophages on CD163 immunostains was determined based on a semi-quantitative scoring system. MRI and histology data were compared among patient groups using t tests, analysis of variance, and regression analyses with a significance threshold of p < 0.05. RESULTS: At 4 h p.i., mean T2* values were 6.6 ± 1.5 ms for native kidneys and 3.9 ms for one allograft undergoing acute immune rejection. Surprisingly, at 20-24 h p.i., one rejecting allograft showed significantly prolonged T2* relaxation times (37.0 ms) compared to native kidneys (6.3 ± 1.7 ms) and non-rejecting allografts (7.6 ± 0.1 ms). Likewise, three additional rejecting allografts showed significantly prolonged T2* relaxation times compared to non-rejecting allografts at later post-contrast time points, 25-97 h p.i. (p = 0.008). Histological analysis revealed edema and compressed microvessels in biopsies of rejecting allografts. Allografts with and without rejection showed insignificant differences in macrophage content on histopathology (p = 0.44). CONCLUSION: After ferumoxytol administration, renal allografts undergoing acute rejection show prolonged T2* values compared to non-rejecting allografts. Since histology revealed no significant differences in macrophage content, the increasing T2* value is likely due to the combined effect of reduced perfusion and increased edema in rejecting allografts.
Entities:
Keywords:
Ferumoxytol; Iron oxide nanoparticles; Kidney allograft rejection; MR imaging
Authors: Elizabeth A Sadowski; Sean B Fain; Sara K Alford; Frank R Korosec; Jason Fine; Rebecca Muehrer; Arjang Djamali; R Michael Hofmann; Bryan N Becker; Thomas M Grist Journal: Radiology Date: 2005-09 Impact factor: 11.105
Authors: Arjang Djamali; Elizabeth A Sadowski; Rebecca J Muehrer; Shannon Reese; Chanigan Smavatkul; Aparna Vidyasagar; Sean B Fain; Ryan C Lipscomb; Debra H Hullett; Millie Samaniego-Picota; Thomas M Grist; Bryan N Becker Journal: Am J Physiol Renal Physiol Date: 2006-10-24
Authors: Yijen L Wu; Qing Ye; Danielle F Eytan; Li Liu; Bedda L Rosario; T Kevin Hitchens; Fang-Cheng Yeh; Nico Rooijen van; Chien Ho Journal: Circ Cardiovasc Imaging Date: 2013-10-04 Impact factor: 7.792
Authors: M Haas; B Sis; L C Racusen; K Solez; D Glotz; R B Colvin; M C R Castro; D S R David; E David-Neto; S M Bagnasco; L C Cendales; L D Cornell; A J Demetris; C B Drachenberg; C F Farver; A B Farris; I W Gibson; E Kraus; H Liapis; A Loupy; V Nickeleit; P Randhawa; E R Rodriguez; D Rush; R N Smith; C D Tan; W D Wallace; M Mengel Journal: Am J Transplant Date: 2014-02 Impact factor: 8.086
Authors: Heike E Daldrup-Link; Ashok J Theruvath; Ali Rashidi; Michael Iv; Robbie G Majzner; Sheri L Spunt; Stuart Goodman; Michael Moseley Journal: Pediatr Radiol Date: 2021-05-27